Press Releases & News Archives - Page 2 of 7 - Triumvira Immunologics | Engineered T Cell Therapies
Triumvira Immunologics Updates
Presentation of Clinical Data
Date: June 28, 2023
Locations: AUSTIN, Texas; HAMILTON, ON; SOUTH SAN FRANCISCO, Calif.
Announcement: Triumvira Immunologics will present clinical data on its lead asset TAC01-HER2 for HER2 positive solid tumors at the 2023 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain, held from June 28 – July 1, 2023. The presentation will showcase findings from the ongoing Phase I/II trial of TAC01-HER2 among patients with relapsed or refractory solid tumors.
Quote
"We are honored to share our latest advancements in precision cell therapy at ESMO World Congress. Our innovative and well-differentiated TAC01-HER2 cell therapy holds great promise in the treatment of HER2-positive solid tumors," said Deyaa Adib, M.D., Chief Medical Officer.
Positive Data Presentation
Date: May 31, 2023
Locations: AUSTIN, Texas; HAMILTON, ON; SOUTH SAN FRANCISCO, Calif.
Announcement: Positive data from the Phase I/II trial of autologous TAC01-HER2 in refractory solid tumors (TACTIC-2) will be presented at the 2023 American Society Of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2-6. Benjamin L. Schlechter, MD, will highlight updated clinical data demonstrating the potential of TAC01-HER2.
Quote
"We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D..
Updates at ASCO 2023
Date: May 16, 2023
Announcement: Triumvira will present clinical data on TAC01-HER2 during the ASCO Annual Meeting highlighting updated clinical data from the ongoing Phase I/II trial.
Quote
"We are excited to present the latest clinical data from our Phase I/II trial of TAC01-HER2 in refractory solid tumors at the upcoming ASCO meeting..." said Deyaa Adib, M.D..
AACR Annual Meeting Presentation
Date: April 18, 2023
Announcement: Triumvira will present data at the 2023 AACR Annual Meeting on TAC01-HER2 for HER2 positive solid tumors, including updated clinical data from the ongoing TACTIC-2 trial and preclinical data on allogeneic HER2-TAC T cell products.
Presentation Details
- Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors
- Authors: Ecaterina E. Dumbrava, MD; Daniel Olson, MD; Samuel Saibil, MD; Brooke Pieke; Mridula A. George, MD; Riemke Bouvier; Kelly Gruber; Kara Moss; Nathan Ternus; Maria Apostolopoulou; Deyaa Adib, MD; Benjamin L. Schlechter, MD.
Collaboration with Merck
Date: April 18, 2023
Announcement: Triumvira announced a clinical trial collaboration and supply agreement with Merck to evaluate TAC01-HER2 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab).
Quote
"We believe the addition of an immune checkpoint inhibitor, such as KEYTRUDA, to TAC01-HER2 will effectively release inhibitory PD-L1/PD1 signaling in T cells..." said Paul Lammers, M.D..
Updated Positive Clinical Data
Date: November 10, 2022
Announcement: Updated data from the ongoing TACTIC-2 Phase 1/2 trial of TAC01-HER2 will be shared at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
Interim Data Highlights
- TAC01-HER2 is well-tolerated with clinical activity observed in higher dosing cohorts.
- Notable disease control rate of 67% in the third cohort (n=3).
- Patients demonstrate stable disease, indicating potential clinical benefit.
Preclinical Data Presentation
Date: November 9, 2022
Announcement: Triumvira presented preclinical data for investigational TAC-T cell therapies including CLDN18.2-TAC T and GUCY2C-TAC T.
Quote
"We are encouraged by our preclinical results... our proprietary TAC technology is versatile and can achieve effective and specific tumor targeting," said Andreas Bader, Ph.D..
Leadership Update
Date: October 24, 2022
Announcement: Appointment of Robert Williamson as President and Chief Business Officer, responsible for business development and strategy.
Quote
"We are delighted to welcome Rob to the team and look forward to advancing Triumvira’s mission," said Paul Lammers, M.D..